

Supplementary Table S1. Clinico-pathological characteristics of the cohort of 96 triple-negative breast cancer (TNBC) patients by type of response to neoadjuvant chemotherapy (NAC).

	Partial responders (n=63)	Non-responders (n=33)	<i>p</i>
Age Years, median (IQR)	51.00 (25.00)	55.00 (25.00)	0.452*
Menopausal status			
Pre-menopausal	24 (47.1%)	11 (40.7%)	0.768 [†]
Menopausal	27 (52.9%)	16 (59.3%)	
Histological grade			
< 3	10 (16.7%)	7 (21.9%)	0.741 [†]
3	50 (83.3%)	25 (78.1%)	
Tumour diameter			
mm, median (IQR)	22.00 (21.00)	30.00 (35.00)	0.003*
Nodal status			
Negative	37 (60.7%)	4 (12.1%)	<0.001[†]
Positive	24 (39.3%)	29 (87.9%)	
Ki67 degree			
≤ 30%	14 (25.9%)	10 (31.3%)	0.777 [†]
> 30%	40 (74.1%)	22 (68.8%)	
Surgery			
Tumorectomy	26 (42.6%)	10 (30.3%)	0.342 [†]
Mastectomy	35 (57.4%)	23 (69.7%)	
No lymphadenectomy	17 (27.9%)	3 (9.1%)	0.063 [†]
Lymphadenectomy	44 (72.1%)	30 (90.9%)	
Adjuvant treatment			
No	51 (83.6%)	26 (81.3%)	1.000 [†]
Yes	10 (16.4%)	6 (18.8%)	
Radiotherapy			
No	4 (4.6%)	0 (0.0%)	0.295 [†]
Yes	54 (93.1%)	30 (100.0%)	
Relapse			
No	40 (63.5%)	14 (43.8%)	0.106 [†]
Yes	23 (36.5%)	18 (56.3%)	
Overall survival (median months (IQR))	59.80 (34.93)	38.37 (36.17)	0.026*
Relapse-free survival (median months (IQR))	45.47 (45.80)	29.53 (40.13)	0.056*
Status			
Alive	42 (66.7%)	17 (51.5%)	0.219 [†]
Dead	21 (33.3%)	16 (48.5%)	

Data are presented as the median and interquartile range (Mann–Whitney U test, *), and the number and percentage of patients in each category (chi-squared test, [†]). Age, menopausal status, histological grade, tumour diameter, nodal status, and Ki67 degree were recorded at the time of diagnosis. Overall survival and relapse-free survival were censored at 60 months.